Novartis shares slip, Avidity soars after $12 billion biotech deal
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CE... ...